Stock Events

Stock Events

CytoMed Therapeutics 

$1.03
0
+$0+0% Today

Statistics

Day High
1.03
Day Low
0.97
52W High
-
52W Low
-
Volume
6,443
Avg. Volume
-
Mkt Cap
11.89B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MayExpected
Q2 2024
Q2 2025
Next
-0.07
0.26
0.6
0.93
Expected EPS
N/A
Actual EPS
N/A

Financials

-3,602.19%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
102,429.78Revenue
-3.69MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GDTC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops similar therapies in the field of immunology and infectious diseases, directly competing with CytoMed's product lines.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments in areas that overlap with CytoMed's research in immune modulation and targeted therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, particularly in monoclonal antibodies, a field that competes with CytoMed's biologic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other serious diseases, competing in the specialty biotech sector alongside CytoMed.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on advanced biologics for neurological diseases and its expansion into immunology make it a direct competitor in the biopharmaceutical space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in similar therapeutic areas including immunology and oncology, directly competing with CytoMed's research and development efforts.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company that develops prescription medicines and biologic therapies, competing across several of CytoMed's key areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer's broad range of biopharmaceutical products and its investment in biotechnology research make it a competitor in multiple therapeutic areas covered by CytoMed.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that produces drugs in nearly all of the same categories as CytoMed, making it a significant competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates globally in biopharmaceuticals, focusing on several of the same disease areas as CytoMed, particularly in oncology and respiratory diseases.

About

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Show more...
CEO
ISIN
SGXZ17669631

Listings

XNAS
US
GDTC
F
DE
F98.F
BOATS
BOATS
GDTC.BOATS

0 Comments

Share your thoughts

FAQ

What is CytoMed Therapeutics stock price today?▼
The current price of GDTC.BOATS is $1.03 USD — it has increased by +0% in the past 24 hours. Watch CytoMed Therapeutics stock price performance more closely on the chart.
What is CytoMed Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CytoMed Therapeutics stocks are traded under the ticker GDTC.BOATS.
What is CytoMed Therapeutics market cap?▼
Today CytoMed Therapeutics has the market capitalization of 11.89B
When is the next CytoMed Therapeutics earnings date?▼
CytoMed Therapeutics is going to release the next earnings report on May 04, 2026.
What is CytoMed Therapeutics revenue for the last year?▼
CytoMed Therapeutics revenue for the last year amounts to 102,429.78 USD.
What is CytoMed Therapeutics net income for the last year?▼
GDTC.BOATS net income for the last year is -3.69M USD.
When did CytoMed Therapeutics complete a stock split?▼
CytoMed Therapeutics has not had any recent stock splits.